BioSymetrics offers the Elion platform, a phenomics‑driven system that combines massive clinical and genomic datasets with high‑content zebrafish experiments to predict and validate disease‑relevant targets. Its patented Contingent‑AI™ performs virtual phenotypic screening and rapidly ranks gene targets and mechanisms of action, while an automated zebrafish pipeline provides in vivo validation within weeks. The platform is aimed at pharmaceutical and biotech companies developing precision medicines for neurological, cardiometabolic, and rare diseases.
Funding
$6.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Clinical drug discovery suffers from high failure rates because target selection often relies on reductionist methods that do not capture the complexity of human disease biology, leading to low efficacy in trials.
Solution
BioSymetrics addresses this gap with its Elion platform, a phenomics‑driven system that integrates massive clinical datasets (over 77 million longitudinal patient records and 1 million genomic profiles) with high‑content zebrafish experiments. Contingent‑AI™ learns relationships across these heterogeneous data sources to perform virtual phenotypic screening, predicting novel gene targets and mechanisms of action. Predicted targets are rapidly validated in vivo using automated 96‑well zebrafish assays and computer‑vision analysis, delivering high‑confidence candidates within weeks. By grounding discoveries in human genetic evidence, the platform increases the likelihood of clinical success for precision medicines in neurological, cardiometabolic, and rare disease areas.
Target Audience
Primary customers are pharmaceutical companies and biotech firms seeking AI‑enhanced target discovery and rapid in vivo validation for neurological, cardiometabolic, and rare disease programs.
Features
- Patented Contingent‑AI™ that links clinical EMR data, genomics, and experimental phenomics to uncover disease‑relevant targets
- Virtual phenotypic screening that predicts gene targets and drug mechanisms before any wet‑lab work
- Scalable zebrafish validation pipeline with automated 96‑well plate handling and computer‑vision models for morphology, blood flow, and organ volume analysis
- Mechanism‑of‑Action prediction workflow that clusters, denoises, and enriches public datasets to generate ranked compound lists and pathway insights in under three weeks
- Integration of human genetic evidence to prioritize targets with twice the typical clinical success probability
- Focused programs in epilepsy, cardiometabolic disorders, and rare diseases, leveraging both common and rare disease models